APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Checkpoint Inhibitors for Treating Cancer

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Selected research

Industry Growth & Trends

Global Checkpoint Inhibitors for Treating Cancer Industry Growth and Trends Forecast to 2032

Report ID 17397683011 January 202672 pages

Choose your research edition.

Industry ResearchCheckpoint Inhibitors for Treating Cancer Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Checkpoint Inhibitors for Treating Cancer Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Checkpoint Inhibitors for Treating Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Checkpoint Inhibitors for Treating Cancer Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Checkpoint Inhibitors for Treating Cancer Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Checkpoint Inhibitors for Treating Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Checkpoint Inhibitors for Treating Cancer market size, estimates, and forecasts are presented in terms of sales volume (g) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Checkpoint Inhibitors for Treating Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Checkpoint Inhibitors for Treating Cancer.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Checkpoint Inhibitors for Treating Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Checkpoint Inhibitors for Treating Cancer Market by Company

Bristol-Myers Squibb(BMS)

Merck

Roche

Checkpoint Inhibitors for Treating Cancer Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

CTLA-4 Inhibitors

Checkpoint Inhibitors for Treating Cancer Segment by Application

Melanoma Treatment

Bladder Cancer Treatment

Other

Checkpoint Inhibitors for Treating Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Checkpoint Inhibitors for Treating Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Checkpoint Inhibitors for Treating Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Checkpoint Inhibitors for Treating Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Checkpoint Inhibitors for Treating Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of PD-1 Inhibitors Table 2. Major Company of PD-L1 Inhibitors Table 3. Major Company of CTLA-4 Inhibitors Table 4. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (g) Table 6. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type (2021-2026) Table 7. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (US$ Million) Table 8. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type (2021-2026) Table 9. Global Checkpoint Inhibitors for Treating Cancer Price by Type (2021-2026) & (US$/mg) Table 10. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2027-2032) & (g) Table 11. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type (2027-2032) Table 12. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2027-2032) & (US$ Million) Table 13. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type (2027-2032) Table 14. Global Checkpoint Inhibitors for Treating Cancer Price by Type (2027-2032) & (US$/mg) Table 15. North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (g) Table 16. North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (g) Table 18. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (g) Table 20. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (g) Table 22. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (g) Table 24. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2026) & (US$ Million) Table 25. Checkpoint Inhibitors for Treating Cancer Industry Trends Table 26. Checkpoint Inhibitors for Treating Cancer Industry Drivers Table 27. Checkpoint Inhibitors for Treating Cancer Industry Opportunities and Challenges Table 28. Checkpoint Inhibitors for Treating Cancer Industry Restraints Table 29. Global Checkpoint Inhibitors for Treating Cancer Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2021-2026) Table 31. Global Checkpoint Inhibitors for Treating Cancer Sales by Company (2021-2026) & (g) Table 32. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Company (2021-2026) Table 33. Global Checkpoint Inhibitors for Treating Cancer Market Price by Company (2021-2026) & (US$/mg) Table 34. Global Checkpoint Inhibitors for Treating Cancer Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Checkpoint Inhibitors for Treating Cancer Major Company Production Sites and Headquarters Table 36. Global Checkpoint Inhibitors for Treating Cancer Company, Product Type & Application Table 37. Global Checkpoint Inhibitors for Treating Cancer Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Checkpoint Inhibitors for Treating Cancer Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2026) & (g) Table 42. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Region (2021-2026) Table 43. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2026) & (US$ Million) Table 44. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Region (2021-2026) Table 45. Global Checkpoint Inhibitors for Treating Cancer Sales (g), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 46. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2027-2032) & (g) Table 47. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Region (2027-2032) Table 48. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2027-2032) & (US$ Million) Table 49. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Region (2027-2032) Table 50. Global Checkpoint Inhibitors for Treating Cancer Sales (g), Value (US$ Million), Price (US$/mg) and Gross Margin (2027-2032) Table 51. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (g) Table 53. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application (2021-2026) Table 54. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (US$ Million) Table 55. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application (2021-2026) Table 56. Global Checkpoint Inhibitors for Treating Cancer Price by Application (2021-2026) & (US$/mg) Table 57. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2027-2032) & (g) Table 58. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application (2027-2032) Table 59. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2027-2032) & (US$ Million) Table 60. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application (2027-2032) Table 61. Global Checkpoint Inhibitors for Treating Cancer Price by Application (2027-2032) & (US$/mg) Table 62. North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (g) Table 63. North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (g) Table 65. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (g) Table 67. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (g) Table 69. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (g) Table 71. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (US$ Million) Table 72. Bristol-Myers Squibb(BMS) Company Information Table 73. Bristol-Myers Squibb(BMS) Business Overview Table 74. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 75. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Portfolio Table 76. Bristol-Myers Squibb(BMS) Recent Development Table 77. Merck Company Information Table 78. Merck Business Overview Table 79. Merck Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 80. Merck Checkpoint Inhibitors for Treating Cancer Product Portfolio Table 81. Merck Recent Development Table 82. Roche Company Information Table 83. Roche Business Overview Table 84. Roche Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 85. Roche Checkpoint Inhibitors for Treating Cancer Product Portfolio Table 86. Roche Recent Development Table 87. North America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (g): 2021 VS 2025 VS 2032 Table 88. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (g) Table 89. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026) Table 90. North America Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (g) Table 91. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Country (2027-2032) Table 92. North America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 93. North America Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026) & (US$ Million) Table 94. North America Checkpoint Inhibitors for Treating Cancer Market Share by Country (2021-2026) Table 95. North America Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 96. North America Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country (2027-2032) Table 97. Europe Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (g): 2021 VS 2025 VS 2032 Table 98. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (g) Table 99. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026) Table 100. Europe Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (g) Table 101. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Country (2027-2032) Table 102. Europe Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 103. Europe Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026) & (US$ Million) Table 104. Europe Checkpoint Inhibitors for Treating Cancer Market Share by Country (2021-2026) Table 105. Europe Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 106. Europe Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country (2027-2032) Table 107. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (g): 2021 VS 2025 VS 2032 Table 108. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (g) Table 109. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026) Table 110. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (g) Table 111. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Country (2027-2032) Table 112. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026) & (US$ Million) Table 114. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Share by Country (2021-2026) Table 115. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country (2027-2032) Table 117. Latin America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (g): 2021 VS 2025 VS 2032 Table 118. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (g) Table 119. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026) Table 120. Latin America Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (g) Table 121. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Country (2027-2032) Table 122. Latin America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Latin America Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026) & (US$ Million) Table 124. Latin America Checkpoint Inhibitors for Treating Cancer Market Share by Country (2021-2026) Table 125. Latin America Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Latin America Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country (2027-2032) Table 127. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (g): 2021 VS 2025 VS 2032 Table 128. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (g) Table 129. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026) Table 130. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (g) Table 131. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Country (2027-2032) Table 132. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026) & (US$ Million) Table 134. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Share by Country (2021-2026) Table 135. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country (2027-2032) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Checkpoint Inhibitors for Treating Cancer Distributors List Table 140. Checkpoint Inhibitors for Treating Cancer Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Checkpoint Inhibitors for Treating Cancer Image Figure 2. Global Checkpoint Inhibitors for Treating Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Checkpoint Inhibitors for Treating Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Checkpoint Inhibitors for Treating Cancer Sales (2021-2032) & (g) Figure 5. PD-1 Inhibitors Image Figure 6. Global PD-1 Inhibitors Sales YoY Growth (2021-2032) & (g) Figure 7. PD-L1 Inhibitors Image Figure 8. Global PD-L1 Inhibitors Sales YoY Growth (2021-2032) & (g) Figure 9. CTLA-4 Inhibitors Image Figure 10. Global CTLA-4 Inhibitors Sales YoY Growth (2021-2032) & (g) Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Checkpoint Inhibitors for Treating Cancer Market Share by Type 2025 VS 2032 Figure 13. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type in 2025 Figure 14. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type in 2025 Figure 15. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type in 2025 Figure 16. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type in 2025 Figure 19. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Checkpoint Inhibitors for Treating Cancer Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Melanoma Treatment Image Figure 26. Global Melanoma Treatment Sales YoY Growth (2021-2032) & (g) Figure 27. Bladder Cancer Treatment Image Figure 28. Global Bladder Cancer Treatment Sales YoY Growth (2021-2032) & (g) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (g) Figure 31. Global Checkpoint Inhibitors for Treating Cancer Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Checkpoint Inhibitors for Treating Cancer Market Share by Application 2025 VS 2032 Figure 33. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application in 2025 Figure 34. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application in 2025 Figure 35. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application in 2025 Figure 36. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application in 2025 Figure 39. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application in 2025 Figure 43. North America Checkpoint Inhibitors for Treating Cancer Sales by Country: 2021 VS 2025 VS 2032 (g) Figure 44. North America Checkpoint Inhibitors for Treating Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Checkpoint Inhibitors for Treating Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country: 2021 VS 2025 VS 2032 (g) Figure 48. Europe Checkpoint Inhibitors for Treating Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Checkpoint Inhibitors for Treating Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Country: 2021 VS 2025 VS 2032 (g) Figure 52. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country: 2021 VS 2025 VS 2032 (g) Figure 56. Latin America Checkpoint Inhibitors for Treating Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Checkpoint Inhibitors for Treating Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country: 2021 VS 2025 VS 2032 (g) Figure 60. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Checkpoint Inhibitors for Treating Cancer Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Checkpoint Inhibitors for Treating Cancer Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
Applications
  • Melanoma Treatment
  • Bladder Cancer Treatment
  • Other
Companies covered
  • Bristol-Myers Squibb(BMS)
  • Merck
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Checkpoint Inhibitors for Treating Cancer Market by Type
  6. 1.3.1 PD-1 Inhibitors
  7. 1.3.2 PD-L1 Inhibitors
  8. 1.3.3 CTLA-4 Inhibitors
  9. 1.4 Global Checkpoint Inhibitors for Treating Cancer Market Size by Type
  10. 1.4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Checkpoint Inhibitors for Treating Cancer Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
  2. 2.2 Checkpoint Inhibitors for Treating Cancer Industry Drivers
  3. 2.3 Checkpoint Inhibitors for Treating Cancer Industry Opportunities and Challenges
  4. 2.4 Checkpoint Inhibitors for Treating Cancer Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Checkpoint Inhibitors for Treating Cancer Revenue (2021-2026)
  2. 3.2 Global Top Players by Checkpoint Inhibitors for Treating Cancer Sales (2021-2026)
  3. 3.3 Global Top Players by Checkpoint Inhibitors for Treating Cancer Price (2021-2026)
  4. 3.4 Global Checkpoint Inhibitors for Treating Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Checkpoint Inhibitors for Treating Cancer Major Company Production Sites & Headquarters
  6. 3.6 Global Checkpoint Inhibitors for Treating Cancer Company, Product Type & Application
  7. 3.7 Global Checkpoint Inhibitors for Treating Cancer Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Checkpoint Inhibitors for Treating Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Checkpoint Inhibitors for Treating Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Checkpoint Inhibitors for Treating Cancer Tier 1, Tier 2, and Tier 3
4 Checkpoint Inhibitors for Treating Cancer Regional Status and Outlook
  1. 4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Checkpoint Inhibitors for Treating Cancer Historic Market Size by Region
  3. 4.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Region
  7. 4.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Checkpoint Inhibitors for Treating Cancer Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Checkpoint Inhibitors for Treating Cancer Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Checkpoint Inhibitors for Treating Cancer by Application
  1. 5.1 Checkpoint Inhibitors for Treating Cancer Market by Application
  2. 5.1.1 Melanoma Treatment
  3. 5.1.2 Bladder Cancer Treatment
  4. 5.1.3 Other
  5. 5.2 Global Checkpoint Inhibitors for Treating Cancer Market Size by Application
  6. 5.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Checkpoint Inhibitors for Treating Cancer Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bristol-Myers Squibb(BMS)
  2. 6.1.1 Bristol-Myers Squibb(BMS) Company Information
  3. 6.1.2 Bristol-Myers Squibb(BMS) Business Overview
  4. 6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Portfolio
  6. 6.1.5 Bristol-Myers Squibb(BMS) Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck Checkpoint Inhibitors for Treating Cancer Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 Roche
  14. 6.3.1 Roche Company Information
  15. 6.3.2 Roche Business Overview
  16. 6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Roche Checkpoint Inhibitors for Treating Cancer Product Portfolio
  18. 6.3.5 Roche Recent Developments
7 North America by Country
  1. 7.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country
  2. 7.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
  4. 7.1.3 North America Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032)
  5. 7.2 North America Checkpoint Inhibitors for Treating Cancer Market Size by Country
  6. 7.2.1 North America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026)
  8. 7.2.3 North America Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country
  2. 8.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
  4. 8.1.3 Europe Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Checkpoint Inhibitors for Treating Cancer Market Size by Country
  6. 8.2.1 Europe Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026)
  8. 8.2.3 Europe Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Country
  2. 9.1.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size by Country
  6. 9.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Checkpoint Inhibitors for Treating Cancer Sales by Country
  2. 10.1.1 South America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
  4. 10.1.3 South America Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032)
  5. 10.2 South America Checkpoint Inhibitors for Treating Cancer Market Size by Country
  6. 10.2.1 South America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026)
  8. 10.2.3 South America Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country
  2. 11.1.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size by Country
  6. 11.2.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Checkpoint Inhibitors for Treating Cancer Value Chain Analysis
  2. 12.1.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Checkpoint Inhibitors for Treating Cancer Production Mode & Process
  7. 12.2 Checkpoint Inhibitors for Treating Cancer Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Checkpoint Inhibitors for Treating Cancer Distributors
  10. 12.2.3 Checkpoint Inhibitors for Treating Cancer Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst